Multiple Myeloma Experts, Patients, Advocates and Caregivers Team Up to Hike Through Patagonia
Retrieved on:
Tuesday, October 22, 2019
Research, Women, Hospitals, MEN, Other Health, Pharmaceutical, Consumer, Health, Science, Oncology, Drugs, Medicine, Clinical medicine, RTT, Orphan drugs, Takeda Pharmaceutical Company, Norwalk, Connecticut, Immunosuppressants, Lenalidomide, Multiple myeloma, Bortezomib, Multiple Myeloma Research Foundation, Moving Mountains for Multiple Myeloma®, Multiple Myeloma, the Multiple Myeloma Research Foundation, CURE Media Group
The upcoming climb includes survivors, caregivers, family members, myeloma doctors and team members from the organizing partners.
Key Points:
- The upcoming climb includes survivors, caregivers, family members, myeloma doctors and team members from the organizing partners.
- All the funds raised go directly to the MMRF to accelerate new treatment options for patients with multiple myeloma.
- She began her treatment with the multiple myeloma standard induction therapy of Revlimid (lenalidomide), bortezomib (Velcade) and dexamethasone for four months.
- Moving Mountains for Multiple Myeloma (MM4MM) is a collaboration between CURE Media Group and the Multiple Myeloma Research Foundation (MMRF) to raise awareness and funds for myeloma research.